Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANK-2 NK cell immunotherapy with salvage chemotherapy for relapsed or refractory acute leukemia
2012-005146-38Phase 2Terminated
- Sponsor
- ANTONIO PEREZ MARTINEZ
- Start
- Nov 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical expanded and activated natural killer cells, aldesleukin in Acute Leukaemia, acute lymphoblastic leukemia (ALL), sponsored by ANTONIO PEREZ MARTINEZ. Started Nov 2012; status: terminated.
02
Drugs
haploidentical expanded and activated natural killer cellsaldesleukin
03
Conditions
Acute Leukaemiaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2012-005146-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005146-38.